Moreover, in the realm of immunotherapy, there are clues suggesting that the combination of ICB therapy with anti-CD38/anti-CD74 complexes or ICB therapy combined with CCR5 inhibitors may ameliorate the immune suppression caused by BAP1 deficiency [12, 32], while these strategies have not yet entered the clinical trial stage. Here, BAP1 is linked to hyperinsulinemic hypoglycemia, familial, 4.